Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HPS-4/TIMI 65/ORION-4: A Double-blind Randomized Placebo-controlled Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Atherosclerotic Cardiovascular Disease

Trial Profile

HPS-4/TIMI 65/ORION-4: A Double-blind Randomized Placebo-controlled Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Atherosclerotic Cardiovascular Disease

Recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Nov 2018

At a glance

  • Drugs Inclisiran (Primary)
  • Indications Hypercholesterolaemia
  • Focus Adverse reactions; Registrational
  • Acronyms HPS-4/TIMI 65/ORION-4; ORION-4
  • Sponsors The Medicines Company
  • Most Recent Events

    • 10 Oct 2018 Status changed from not yet recruiting to recruiting.
    • 10 Oct 2018 Status changed from planning to not yet recruiting.
    • 25 Jan 2018 According to The Medicines Company media release, the company anticipate completion of the trial to include the results in an NDA planned for the end of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top